Delivery Order SPE2DB20D1100-SPE2DB25FD9M0
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $20,578.74 to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) under a firm fixed-price contract type. The award was made on August 4, 2025, with an ultimate completion date of August 5, 2025, and represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, performed the work at its corporate office location and serves as a critical...
- The Defense Logistics Agency awarded a delivery order valued at $1,599.24 to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of XELJANZ XR 11 MG tablets in quantities of 30 units. This firm fixed-price delivery order represents a non-set-aside competitive award and is scheduled for completion by July 22, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement....
- The Defense Logistics Agency awarded a delivery order valued at $8,137.72 to AmerisourceBergen Drug Corp for XELJANZ XR 11 MG tablets (30-count units) on August 4, 2025, with completion scheduled for August 5, 2025. This firm fixed-price delivery order represents a non-set-aside competitive procurement supporting federal pharmaceutical supply needs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for...
- The Defense Logistics Agency awarded a delivery order valued at $5,737.25 to AmerisourceBergen Drug Corp for XELJANZ XR 11 MG tablets in quantities of 30 units. This firm fixed-price delivery order was competitively awarded without set-aside designation and is scheduled for completion by August 12, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfills this order as part of its critical role in the federal medical supply...
- The Defense Logistics Agency awarded a delivery order valued at $13,322.71 to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) on August 6, 2025, with completion expected by August 7, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a continuation of AmerisourceBergen's pharmaceutical supply relationship with DLA. The product will be delivered to AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a $1,599.24 delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) under a firm fixed-price contract, with an ultimate completion date of June 17, 2025. This non-set-aside award was competitively procured and represents a single delivery order fulfilling federal pharmaceutical supply requirements. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a...
- The Defense Logistics Agency awarded a delivery order valued at $9,926.00 to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) on August 7, 2025, with an ultimate completion date of August 8, 2025. This firm fixed-price delivery order is not set-aside and was competitively awarded. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement, particularly supporting...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,491.03 to AmerisourceBergen Drug Corp for the supply of XELJANZ XR 11 MG tablets (30-count units). This firm fixed-price delivery order was competitively awarded without a set-aside designation and is scheduled for completion by July 22, 2025. The contract represents a single transaction under AmerisourceBergen's larger pharmaceutical supply agreement with the federal government, with performance taking place at the...
- The Defense Logistics Agency awarded a $2,477.39 delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 MG tablets (30-count units) under a firm fixed price contract. This non-set-aside award, issued on August 1, 2025, with completion targeted for August 4, 2025, represents a routine pharmaceutical procurement supporting federal medical supply requirements. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for the Defense...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,874.93 to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) on August 7, 2025, with an ultimate completion date of August 8, 2025. This firm fixed-price delivery order was not set-aside and represents a competitive award under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FD9M0Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,956.58 to AmerisourceBergen Drug Corp for the supply of XELJANZ XR 11 mg tablets in quantities of 30 units. This non-set-aside, firm fixed price delivery order was competitively awarded on August 8, 2025, with an ultimate completion date of August 11, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfills this order from its corporate office location. The company serves as a critical vendor for federal medical procurement, supplying a comprehensive range of pharmaceutical products and medical supplies to support military and veteran healthcare systems. This delivery order is issued under AmerisourceBergen Drug Corp's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a potential value of $999,999,999.00 and extends through December 2026. This prime contract vehicle enables the company to supply a broad spectrum of pharmaceutical products and medical commodities globally to support military healthcare programs. The contract encompasses specialty medications, brand-name and generic drugs, vaccines, and related medical supplies across multiple therapeutic domains, serving the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.0k | 8/8/25 |